Eppendorf Award for Young European Investigators opens for entry

Deadline is 15 January 2012

Young researchers working in Europe are invited to apply for the Eppendorf Award for Young European Investigators.

Researchers who are less than 35 have until 15 January 2012 to apply.

The award, inaugurated in 1995, acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts.

An independent expert committee chaired by Kai Simons of the Max Planck Institute for Molecular Cell Biology and Genetics, in Dresden, Germany, will choose the winner.

The successful entrant will receive €15,000 in prize money and an invitation to the prize-giving ceremony at the EMBL Advanced Training Centre in Heidelberg, Germany on 9 May 2012.

In addition, he/she will be invited to Eppendorf in Hamburg and coverage of his/her work will be published in Nature magazine and in a podcast.

The official registration portal is at www.eppendorf.com/award/application. Only online registrations will be accepted.

Full details on the Eppendorf Award, the selection criteria and past award winners, are available at www.eppendorf.com/award.

You may also like

Research & Development

Eppendorf strives to ensure that all labs are smart, safe and stress-free

Eppendorf is a leading life science company that develops and sells instruments, consumables and services for liquid handling, sample handling and cell handling in laboratories worldwide
Manufacturing

Eppendorf launches New Brunswick S41i incubator shaker

Six-sided direct-heating profile provides gentle convection circulation of the chamber
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing

Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility

The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Subscribe now